Fig. 5: Effect of carboplatin + pembrolizumab + TUSC2 combination on human immune suppressive cells on KRAS/LKB1 lung metastases in the humanized mouse model.

In-depth immune analysis was performed using multicolor flow-cytometry using lymphoid and myeloid panels which determined regulatory T cells (Treg), MDSC, and the level of the TAM population in lung metastases. a The level of human Treg cells are shown for different treatment groups, b Ratio of CD8+ T/regulatory T cells in tumors, c level of PD-1 expressing human T cells and inhibition of PD-1 expression on T cells by treatments in the tumor microenvironment in humanized mice, d level of human MDSC based on expression of CD33+ HLA-DR−ve population and the changes of MDSC in different treatment groups shown. e Tumor-associated macrophages (TAM) population were analyzed in lung metastasis. M1 and M2 macrophages are shown in different treatment groups. Lin-ve > CD11b+ > CD163+ > HLA-DR⁻ gating strategies were used for determining the M2 macrophages. Statistics are shown at a significance level of p < 0.05 unless otherwise noted. Data are shown as mean percentage ± SD, n = 5. *P < 0.05, **P < 0.005, ***P < 0.0005.